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Cisplatin is used to treat lung cancer; however,  it is also a known carcinogen.  Cyclooxygenase-2 
(COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors.  We investi-
gated the eﬀect of a COX-2 inhibitor,  celecoxib,  on cisplatin-induced lung tumors.  One hundred 
twenty 4-week-old A/J mice were divided into 6 groups: group 1,  no treatment; group 2,  low-dose 
celecoxib (150mg/kg); group 3,  high-dose celecoxib (1,500mg/kg); group 4,  cisplatin alone; group 5,  
cisplatin plus low-dose celecoxib; and group 6,  cisplatin plus high-dose celecoxib.  Mice in groups 4-6 
were administered cisplatin (1.62mg/kg,  i.p.) once a week for 10 weeks between 7 and 16 weeks of age.  
All mice were sacriﬁced at week 30.  Tumor incidence was 15.8ｵ  in group 1,  25ｵ  in group 2,  26.3ｵ  
in group 3,  60ｵ  in group 4,  50ｵ  in group 5,  and 50ｵ  in group 6.  Tumor multiplicity was 0.2,  0.3,  
0.3,  1.3,  1.0,  and 0.6 in groups 1-6,  respectively.  Tumor multiplicity in the cisplatin-treated mice was 
reduced by celecoxib treatment in a dose-dependent manner (p＜0.05,  group 4 vs.  group 6).  Celecoxib 
signiﬁcantly reduced COX-2 expression in cisplatin-induced tumors (p＜0.01,  group 4 vs.  group 6).
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ung cancer is a leading cause of cancer mortal-
ity in most developed countries,  with a ﬁve-year 
survival rate less than 15ｵ [1].  In recent years,  
improvements in lung cancer therapy (chest radio-
therapy and cisplatin-based chemotherapy) have 
increased the survival rate in lung cancer patients.  
[2,  3].  Thus,  second primary cancers involving 
small-cell lung cancer have increased [4].  The risk of 
secondary lung cancer in patients with non-small-cell 
lung cancer has been estimated to be 1-2ｵ per 
patient per year [5],  whereas the risk for patients 
with small-cell lung cancer has increased to＞2-10ｵ 
per patient per year 10 years after the initial treat-
ment [5].  Cisplatin is widely used in the treatment of 
malignant diseases; however,  it has also been shown 
to be a carcinogen in experimental animals [6].
　 Non-steroidal anti-inﬂammatory drugs (NSAIDs) 
inhibit the cyclooxygenase (COX) enzyme family.  The 
COX enzyme has 2 isoforms: COX-1,  a housekeeping 
enzyme that is constitutively expressed in most tissues 
[7,  8],  and COX-2,  which is typically undetectable 
under basal conditions; however,  it is expressed in 
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response to stimulation with growth factors and 
inﬂammatory cytokines [9,  10].  COX-2 is commonly 
overexpressed in malignant tumors in human and ani-
mal models [11-15],  suggesting a causative associa-
tion between increased COX-2 expression and tumori-
genesis.  Several investigations have studied the 
eﬃcacy of COX-2 as an anticancer therapeutic agent.  
For example,  the COX-2-speciﬁc inhibitor NS398 
inhibited mouse lung tumorigenesis induced by chronic 
administration of tobacco-speciﬁc nitrosamine-4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
[16-18].  Celecoxib has been reported to cause col-
orectal adenoma [19] and colorectal polyps to regress 
[20] and to prevent the formation of colorectal ade-
nomas and cancers [21-22].
　 We previously demonstrated that (－)－epigallo-
catechin gallate prevented cisplatin-induced lung tum-
origenesis in A/J mice [23].  We observed COX-2 
overexpression in cisplatin-induced lung tumors in the 
present study,  and subsequently investigated the eﬃ-
cacy of celecoxib in preventing cisplatin-induced tum-
origenesis in the A/J mouse model.
Materials and Methods
　 Animals and chemicals. We studied 120 
4-week-old female A/J mice (Jackson Laboratories,  
Bar Harbor,  ME,  USA) weighing approximately 15g 
each.  The animals were housed ﬁve per plastic cage 
and were given free access to tap water and standard 
laboratory chow (MF; Oriental Yeast Co.,  Ltd,  
Tokyo,  Japan).  The mice were kept in an air-condi-
tioned room maintained at 55 ± 10ｵ humidity with a 
12-h light/dark cycle in the Animal Center for Medical 
Research,  Okayama University Medical School.  The 
celecoxib and cisplatin were kindly provided by 
Pharmacia,  Ltd.  (Tokyo,  Japan) and Nippon Kayaku 
Co.,  Ltd.  (Tokyo,  Japan),  respectively.
　 Experiment design. Mice were treated in 
accordance with the guidelines of the Okayama 
Universityʼs Institutional Committee on the Treatment 
of Experimental Animals.  The animals were divided 
into 6 groups of 20: group 1,  no treatment control;  
group 2,  low-dose celecoxib (150mg/kg,  diet); group 
3,  high-dose celecoxib (1,500mg/kg,  diet); group 4,  
cisplatin treatment; group 5,  cisplatin plus low-dose 
celecoxib (150mg/kg,  diet); and group 6,  cisplatin 
plus high-dose celecoxib (1,500mg/kg,  diet).  Mice in 
groups 4-6 were treated with cisplatin (1.62mg/kg,  
i.p.) once a week for 10 weeks between 7 and 16 weeks 
of age.  Between 5 and 30 weeks of age,  mice in groups 
2,  3,  5,  and 6 were exclusively fed the experimental 
diet prepared by mixing celecoxib into the standard 
chow.  All mice were sacriﬁced at week 30,  and the 
number of tumors on the lung surface of each mouse 
was determined.
　 Immunohistochemistry. The lungs were 
inﬂated with 10ｵ formalin,  embedded in paraﬃn,  and 
cut into several 4-µm-thick sagittal sections around the 
greatest dimension of the lung.  Tissue sections were 
deparaﬃnized in xylene and washed in ethanol.  
Endogenous peroxidase activity was then inhibited 
using 0.3ｵ H2O2 followed by antigen retrieval.  Slides 
were blocked with rabbit serum antibody (Vector 
Laboratories,  Burlingame,  CA,  USA).  A polyclonal 
rabbit anti-murine COX-2 primary antibody (Cayman 
Chemical,  Ann Arbor,  MI,  USA) was added at a 
1 : 200 dilution.  Biotin-conjugated secondary antibody 
(Vector) was applied and incubated with avidin biotin 
enzyme reagent (Vector).  Then,  diaminobenzidine 
(DAB,  Vector) as a peroxidase substrate was applied.  
The sections were rinsed in H2O,  counterstained with 
methyl green,  dehydrated,  and covered with a xylene-
based mounting medium.
　 COX-2 expression was evaluated in 100 cells from 
each tumor.  The cells expressing COX-2 per high-
power microscope ﬁeld (×400) were counted 3 times.
　 Statistical analysis. The Studentʼs t-test and 
chi-square test were used to assess the relationship 
among categorical variables.  The results are 
expressed as means ± standard errors,  and p-values 
＜0.05 were deemed to be statistically signiﬁcant.
Results
　 Fig.  1A shows hematoxylin and eosin staining of a 
cisplatin-induced tumor from group 4.  Table 1 shows 
the tumor incidence and multiplicity in each group.  
The tumor incidence was 60ｵ (12/20),  50ｵ (10/20),  
and 50ｵ (10/20) in groups 4 (cisplatin alone),  5 (cis-
platin plus low-dose celecoxib),  and 6 (cisplatin plus 
high-dose celecoxib),  respectively.  Thus,  celecoxib 
treatment did not signiﬁcantly reduce tumor incidence.  
However,  mice treated with cisplatin alone developed 
1.3 ± 0.3 tumors per mouse,  whereas mice treated 
with cisplatin plus high-dose celecoxib developed 0.6 
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± 0.1 tumors per mouse,  indicating that high-dose 
celecoxib signiﬁcantly reduced the number of cispla-
tin-induced lung tumors (p＜0.05).  No diﬀerences in 
tumor incidence or multiplicity were found among 
groups 1 (control),  2 (low-dose celecoxib),  and 3 
(high-dose celecoxib) mice.
　 The analysis of COX-2 expression in the tumors 
revealed intense COX-2 staining in the cisplatin-
induced tumor cells (group 4; Fig.  1B,  1C).  In con-
trast,  COX-2 expression was weak in the cisplatin-
induced tumors treated with high-dose celecoxib 
(group 6; Fig.  2).  Fig.  3 shows that the high dose of 
celecoxib signiﬁcantly reduced the percentage of cells 
overexpressing COX-2 (p＜0.01).
　 After the initiation of cisplatin treatment at week 
7,  the body weight of the mice in groups 4,  5,  and 6 
was lower than that of the mice in the non-cisplatin 
groups (1,  2,  and 3; Fig.  4).  However,  the mice in 
group 5 (cisplatin plus low-dose celecoxib) did not lose 
weight after the administration of cisplatin.  Thus,  
low-dose celecoxib prevented cisplatin-induced weight 
loss,  and the mice in group 5 weighed signiﬁcantly 
more than did the mice that received cisplatin alone 
(group 4) at week 30 (p＜0.05).
Discussion
　 Pulmonary tumors have been reported to occur in 
A/J mice 18 weeks after cisplatin treatment [14].  In 
the present study,  we demonstrated that COX-2 was 
overexpressed in cisplatin-induced lung tumors.  
Furthermore,  we found that administration of high-
dose celecoxib signiﬁcantly reduced tumor multiplicity 
and reduced the number of COX-2-expressing tumor 
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Fig. 1　 Hematoxylin and eosin and immunohistochemical staining in cisplatin-induced tumors.  (A) Lung tumor stained with hematoxylin 
and eosin (×250).  (B) Lung tumor stained with COX-2 antibody (×250).  The blue-stained tumor cells indicate overexpression of COX-2.  
(C) A higher magniﬁcation of panel B (×400).
Table 1　 The inhibitory eﬀects of celecoxib on gross tumor incidence and multiplicity in A/J mice
Group no. Tumor incidencea Tumor multiplicityb
1 (tap water only) 3/19 (15.8%) 0.2±0.1
2 (celecoxib 150mg/kg) 5/20 (25.0%) 0.3±0.1
3 (celecoxib 1,500mg/kg) 5/19 (26.3%) 0.3±0.1
4 (cisplatin 1.62mg/kg) 12/20 (60.0%) 1.3±0.3
5 (cisplatin 1.62mg/kg＋celecoxib 150mg/kg) 10/20 (50.0%) 1.0±0.3
6 (cisplatin 1.62mg/kg＋celecoxib 1,500mg/kg) 10/20 (50.0%) 0.6±0.1
aDiﬀerence between cisplatin and cisplatin plus celecoxib was not statistically signiﬁcant by chi-square test.
bNumber of tumors per mouse: group 4 vs. group 6, p＜0.05 (Studentʼs t-test).
cells.  To our knowledge,  this is the ﬁrst report show-
ing that a COX-2 inhibitor prevented cisplatin-induced 
tumorigenesis in a mouse model.
　 NSAIDs have been shown to prevent the develop-
ment of various human tumors,  including colon [24-
26],  breast [27],  esophageal [28],  and lung [29] 
neoplasms by inhibiting COX-2 activity.  COX-2 
expression is induced by inﬂammatory disease and in 
response to cytokines,  growth factors,  and other 
tumor promoters.  Additionally,  COX-2 expression 
plays several distinct roles during oncogenesis [24-
29].  The concentration of COX-2 protein has been 
shown to be signiﬁcantly higher in urethane-induced 
tumors and carcinogenesis in A/J mouse lung tissue 
compared with control lung tissue [14].  Furthermore,  
NNK was shown to cause increasingly higher levels of 
COX-2 expression with progressive stages of lung 
carcinogenesis in rats on a high-fat diet [30].  
Moreover,  we reported that COX-2 may play a role in 
the progression from atypical adenomatous hyperpla-
sia to adenocarcinoma in human lung tissue [31].  The 
nature of the association between increased COX-2 
expression and tumorigenesis and the mechanisms 
underlying the COX-2 inhibition of tumorigenesis in 
terms of angiogenesis [32],  apoptosis [33],  and 
inﬂammation [34] remain to be elucidated in our cis-
platin-induced lung tumor model.
　 We found that low-dose celecoxib (group 5) pre-
vented cisplatin-induced weight loss,  and that the mice 
in group 5 weighed signiﬁcantly more than mice 
treated with cisplatin alone (group 4) at week 30.  The 
COX-2 inhibitor JTE-522 has been reported to pre-
vent body weight loss in rats with N-nitrosometh-
ylbenzylamine-induced tumors [30],  choline-deﬁcient 
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Fig. 3　 Eﬀect of celecoxib on COX-2 expression in cisplatin-
induced tumor cells.  The number of COX-2-expressing cells in a 
sample of 100 cells from each cisplatin-induced tumor was counted 
3 times.  Percent COX-2 positive rates (mean ± SE) of group 4 
(cisplatin) and group 6 (cisplatin ＋ celecoxib 1,500mg/kg) were 
26.7 ± 5.0% and 7.9 ± 0.9%, respectively (p＜0.01).  Statistical 
signiﬁcance was determined using Studentʼs t-test.
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Fig. 2　 Hematoxylin and eosin and immunohistochemical staining in cisplatin-induced tumors treated with celecoxib (1,500mg/kg).  (A) 
Lung tumor stained with hematoxylin and eosin (×100).  (B) Lung tumor stained with COX-2 antibody (×100).  The majority of tumor cells 
did not overexpress COX-2.  (C) A higher magniﬁcation of panel B (×400).
rats,  and rats receiving L-amino acid [35].  Carci-
nogens administered to experimental animals are likely 
to cause cachexia,  resulting in weight loss.  A pla-
cebo-controlled study carried out in cachectic patients 
with head and neck or gastrointestinal cancer showed 
a statistically signiﬁcant increase in weight in patients 
receiving celecoxib (200mg twice daily) compared with 
those in the placebo arm [36].  Furthermore,  a phase 
II clinical trial showed that celecoxib (300mg/day for 
4 months) signiﬁcantly increased lean body mass [37].  
In that study,  celecoxib produced a signiﬁcant decrease 
in tumor necrosis factor-α; however,  the mechanism 
by which low-dose celecoxib prevented the loss of body 
weight in our mouse model is not clear.
　 The COX-2 inhibitor rofecoxib is associated with 
an increased cardiovascular risk in patients with a 
history of colorectal adenomas [38].  A pooled analy-
sis of 6 randomized trials comparing celecoxib with a 
placebo showed an increase in cardiovascular risk and 
provided evidence of an interaction between baseline 
cardiovascular risk and the eﬀect of celecoxib [39].  
The authors suggested that the adverse eﬀect of the 
celecoxib was most pronounced in the high-risk 
patients.  In contrast,  other studies found no clear 
association between cardiovascular risk and COX-2 
inhibitors [40]; however,  high-risk patients were at 
increased risk for COX-2 inhibitor-related adverse 
cardiovascular events.  Celecoxib has been found to be 
an eﬀective chemopreventive agent for non-melanoma 
skin cancer in patients at high risk for the disease 
[41].  In that study,  no statistically signiﬁcant diﬀer-
ence was found in the number of adverse cardiovascu-
lar events between participants who received celecoxib 
and those who received the placebo; however,  the 
drug was administered for only 9 months.  In our 
study,  1,500mg/kg of celecoxib was found to be a safe 
dose for long-term treatment in A/J mice.  However,  
it would be necessary to balance the beneﬁcial eﬀects 
and adverse events associated with celecoxib in a 
chemopreventative trial in patients who will receive 
cisplatin treatment in an adjuvant or a neoadjuvant 
setting.
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